[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"blood-pressure-monitoring\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:blood-pressure-monitoring":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,55,80,111,143,168,197,230,259,284,313],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":5},"100611457","accuracy-of-a-cuffless-photoplethysmography-ppg-chest-patch-monitor-for-24-hour-ambulatory-blood-pressure-monitoring-abpm-100611457",false,"NCT07240831","Accuracy of a Cuffless Photoplethysmography (PPG) Chest-Patch Monitor for 24-hour Ambulatory Blood Pressure Monitoring (ABPM)","Accuracy of a Cuffless Photoplethysmography (PPG) Chest-Patch Monitor for 24-hour Ambulatory Blood Pressure Monitoring","PPG ABPM","Inclusion Criteria\n\n* Females and Males subjects 18 years or older (from all skin tones\u002Fcolors)\n* Scheduled for ABPM for hypertension screening, evaluation, or management\n* Subjects capable of using an application temporarily downloaded (for the duration of the study) on a personal smart phone device or on a device provided by the study sponsor\n* Subjects with Atrial fibrillation or Atrial flutter are eligible to participate if standard cuff-based ABPM monitor can capture blood pressure at initialization\n\nExclusion Criteria\n\n* Indication for ABPM is orthostatic hypotension or Postural Orthostatic Tachycardiac Syndrome as indicated on the ABPM referral order\n* Any neurological, psychological, or other condition impairing the ability to provide informed consent or participate in the study\n* Inability to reliably access the Internet via a smart phone\n* Not able to perform standard cuff-based ABPM\n* Average absolute difference between the two arms is greater than 15 mmHg for Systolic Blood Pressure (SBP) or greater than 10 mmHg Diastolic Blood Pressure (DBP) during the initialization\u002Fcalibration phase\n* Subjects with known allergy to adhesives or skin patches\n* Subjects with solid dark tattoos on the area where the PPG-based device is attached\n* Subjects who are unwilling to have their chest hair shaved, if needed, to install the device (the device uses adhesives and needs to be in direct contact with the skin without hair)\n* Subjects who are unwilling to comply with the study instructions (avoid vigorous exercise and showering for 24 hours while the device is in place)","ALL","18 Years",{"count":20,"type":21},600,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aims to validate the accuracy and reliability of blood pressure (BP) estimates obtained over 24 hours using a PPG-based chest-patch device compared to the gold standard ambulatory blood pressure monitoring (ABPM) method using an upper arm cuff-based oscillometric BP device, in both hypertensive and normotensive individuals referred by their provider to undergo a 24-hours ABPM for clinical indication. The Awake\u002FAsleep test, which is the primary test recommended for automated wearable cuffless BP devices that are cuff-calibrated (based on the 2023 European Society of Hypertension (ESH) recommendations for the validation of cuffless blood pressure measuring devices), will be conducted in this study. The secondary aim of the study is to assess the feasibility and convenience of the PPG-based device.",[27,28,29,30],"Blood Pressure","Heart Disease","Hypertension (HTN)","Blood Pressure Monitoring",[32,33,29,34,35,36,37,38,39,40,41,42],"BLOOD PRESSURE","BLOOD PRESSURE MONITORING","CUFFLESS PHOTOPLETHYSMOGRAPHY","PPG","CUFFLESS","vital signs","ABPM","24 hour ABPM","Ambulatory Blood Pressure Monitoring","Ambulatory Blood Pressure","BP","RECRUITING","2026-08-11",{"date":46,"type":47},"2026-08-13","ACTUAL",{"date":49,"type":47},"2025-12-15",{"date":51,"type":21},"2026-10-30",{"name":53,"class":54},"Biobeat Technologies Ltd.","INDUSTRY",{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":62,"sex":17,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":4,"studyType":22,"phases":67,"briefSummary":68,"conditions":69,"keywords":70,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},"100650690","data-collection-study-using-cs-bp-watch-and-pillow-systems-100650690","NCT07749963","Data Collection Study Using CS (CardiacSense) BP (Blood Pressure) Watch and Pillow Systems","A Data Collection Study to Collect Blood Pressure (BP) Data Using the CardiacSense BP Watch and CardiacSense Pillow Systems for Algorithm Development","Main Inclusion Criteria:\n\n1. 50-80 years old.\n2. Ability and willingness to sign and understand an informed consent form.\n3. The participant has a palpable radial pulse in both wrists.\n4. The participant is willing and able to be fitted with the investigational devices, A-line, and reference cuff, and is willing and able to undergo all study procedures, including 1 hour of recording with the investigational devices and A-line.\n5. Participant has good signal quality with the CS Pillow at both wrists.\n6. Participant has good PPG signals in both thumbs.\n7. Participant has good ECG signals using the Watch.\n\nMain Exclusion Criteria:\n\n1. Participant who are currently enrolled in another clinical investigation in which the intervention might compromise the safety of the participant or interfere with the data collected.\n2. Participant who has previously participated in a BP study conducted by CardiacSense.\n3. Participant whose body habitus precludes them from wearing the investigational devices.\n4. Female participants who self-reported as pregnant based on a urine pregnancy test, or who are self-reported as trying to get pregnant or who are breastfeeding.\n5. Participant whose BMI is greater than 35.\n6. Participant with a documented medical history of cardiac arrhythmia or if arrhythmia was detected during the screening.\n7. Participant with diagnosed diabetes mellitus.\n8. Participant with implanted cardiac defibrillators or pacemakers, Ventricular Assist Device (VAD) or other mechanical circulatory support devices, whether intracorporal or extracorporeal.\n9. Participant with stage 4 or stage 5 end-stage renal disease, or participants with arteriovenous shunts.\n10. Participant with pheochromocytoma or primary hyperaldosteronism.\n11. Participant with diagnosed heart failure with New York Heart Association (NYHA) class III\u002FIV, or participants with a history of stroke.\n12. Participant with a known clotting disorders or currently taking a prescription anticoagulants (daily aspirin use is permitted).\n13. Participant with an infection requiring antibiotics.\n14. Participant with autonomic dysfunction (such as orthostatic hypotension or neuropathy).\n15. Participant with peripheral artery disease\n16. Participants with compromised circulation, including Raynaud's syndrome.\n17. Participant has a fracture, severe trauma, or anatomical deformity involving the wrist or fingers intended for placement of the investigational devices, which could interfere with proper fitting or function of the devices.\n18. Participant with moderate to severe valvulopathies.\n19. Participant with primary vasculitis.\n20. Participant with tremors or otherwise unable to remain still for 1 hour.\n21. Participants with changes to their antihypertensive medication regimen, including initiation, discontinuation, or dose modification, within 30 days prior to enrollment.\n22. The left to right arm lateral difference of the average systolic blood pressure values is more than 15 mmHg or the lateral difference of the average diastolic blood pressure values is more than 10 mmHg.\n23. Participant belongs to a recruitment category that has already been filled, including BMI category, height category, age group, sex, skin tone category, or blood pressure classification group.\n24. Participant with contact allergy to ultrasound gel.\n25. Participant with prior or known allergies to lidocaine (or similar pharmacological agents, e.g. Novocaine).\n26. Participant with severe contact allergies to standard adhesives, latex or other materials found in pulse oximetry sensors, ECG electrodes, respiration monitor electrodes or other medical sensors (self-reported).\n27. Participant with other known health conditions, that might put the participant at risk or might jeopardize the quality of the data collected.\n28. Participant that fails the modified Allen's test (Perfusion Index Ulnar\u002FUlnar+Radial Ratio test) (Ratio \\\u003C 0.4).",true,"50 Years","80 Years",{"count":66,"type":21},100,[24],"Collect raw data from CS Watch System, CS BP Pillow System, Arterial line (A-line) and auscultatory cuff measurements in volunteers. The data collected in the study will be used for development of the CS BP algorithms.",[30],[27],"2026-08-09",{"date":44,"type":47},{"date":74,"type":47},"2026-07-21",{"date":76,"type":21},"2026-08-30",{"name":78,"class":54},"CardiacSense Ltd.",1,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":62,"sex":17,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":110},"100648378","wearable-blood-pressure-monitoring-comparison-study-100648378","NCT07719660","Wearable Blood-Pressure Monitoring Comparison Study","Wearable Blood-Pressure Monitoring Comparison Study (WBPMCS)","WBPMCS","Inclusion Criteria:\n\n* Blood pressure measurements can be performed on at least one arm, for example no amputation, dialysis shunt, or obstructive dressing\n* Ability to understand the study information and provide written informed consent\n* For participants in the intensive care unit: an arterial line placed for clinical reasons\n\nExclusion Criteria:\n\n* Wrist circumference exceeds the size range of the investigated wearable devices\n* Physical or medical conditions preventing placement of the wearable devices, including relevant skin lesions, wounds, severe edema, or patient restraint\n* Inability to provide written informed consent","21 Years","85 Years",{"count":91,"type":21},120,"OBSERVATIONAL","The goal of this clinical trial is to compare the accuracy, clinical applicability, and usability of different wearable blood pressure monitoring methods integrated in wearable devices, such as smartwatches, in hospitalized patients. The study evaluates novel photoplethysmography (PPG)-based and wrist-oscillometric blood pressure measurement methods against established clinical reference methods (upper-arm cuff measurements on the general ward and invasive arterial blood pressure monitoring (A-line) in the intensive care unit).\n\nThe main questions the study aims to answer are:\n\n* Can novel blood pressure monitoring methods suitable for integration into wearable devices achieve clinically acceptable agreement with established reference measurements?\n* How does the performance of calibration-dependent wearable devices change over time following calibration?\n* How does the performance of the investigated methods compare with each other?\n* How do the investigated methods perform for patients with different pre-existing conditions ?\n\nTo answer these questions, participants will undergo:\n\n* blood pressure measurements using different wearable devices based on PPG and wrist oscillometry\n* standardized reference blood pressure measurements using an upper-arm cuff (general ward) or an existing invasive arterial line (intensive care unit)\n* repeated measurements over three consecutive days on the general ward to assess calibration stability and measurement reproducibility,",[95,30,96,97,98],"Hypertension","Wearable Devices","Photoplethysmography","Cuff","NOT_YET_RECRUITING","2026-07-22",{"date":102,"type":47},"2026-07-23",{"date":104,"type":21},"2026-07-20",{"date":106,"type":21},"2027-12-31",{"name":108,"class":109},"Technische Universität Dresden","OTHER",2,{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":62,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":22,"phases":121,"briefSummary":122,"conditions":123,"keywords":129,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":79},"100635720","empowering-faith-based-communities-to-provide-personalized-diabetes-self-management-education-and-support-dsmes-in-the-magic-city-100635720","NCT07556354","Empowering Faith-based Communities to Provide Personalized Diabetes Self-management Education and Support (DSMES) in the Magic City","Empowering Faith-based Communities to Provide Personalized Diabetes Self-management Education and Support (DSMES) in the Magic City: A Pilot Study","MCPILOTDSMES","Inclusion Criteria:\n\n* Have a prior diabetes (Type 1, Type 2, or Gestational) or prediabetes diagnosis\n* Are aged 18 or older\n* Live in Jefferson County, Alabama\n* Have never participated in a DSMES program\n\nExclusion Criteria:\n\n* Not a resident of Jefferson County, Alabama\n* Completed a DSMES program",{"count":120,"type":21},30,[24],"In this study, individuals living with diabetes in the Birmingham area will participate in a free, 3-month DSMES program hosted by MedsPLUS Consulting, a local independent pharmacy and wellness center, at a local faith-based organization. DSMES sessions meet twice a month and typically address topics including physical activity, nutrition, coping, and reducing risk and complications. Prior to beginning the program, participants will complete a questionnaire that assesses diabetes self-management behaviors (such as diet, physical activity, and medication adherence) and diabetes knowledge. Additionally, they will participate in a biometric screening where clinical data such as blood A1C, blood pressure, blood cholesterol, and BMI are collected. This data will also be collected again after the completion of the program. In this program, participants will be assigned a community health worker who will contact them outside of scheduled DSMES sessions to provide support. Participants will also be randomly assigned to one of two cohorts, the Traditional cohort and the Remote Patient Monitoring (RPM) cohort. The traditional cohort will use paper trackers to track blood pressure and blood sugar outside of DSMES sessions while the RPM cohort will utilize an RPM platform to track this data.",[124,30,125,126,127,128],"Blood Cholesterol","Weight Change","BMI","Diabetes Education","Diabetes (DM)",[130,131,132,133],"dsmes","diabetes education","faith based intervention","remote patient monitoring","2026-07-14",{"date":136,"type":47},"2026-07-15",{"date":138,"type":21},"2026-07",{"date":140,"type":21},"2026-10",{"name":142,"class":109},"University of Alabama at Birmingham",{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":152,"conditions":153,"keywords":155,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":79},"100612729","pressure-sensing-sheath-blood-pressure-monitoring-compared-to-traditional-methods-in-interventional-procedures-100612729","NCT07257367","Pressure Sensing Sheath Blood Pressure Monitoring Compared to Traditional Methods in Interventional Procedures","Accuracy and Safety Assessment of Pressure Sensing Sheath Blood Pressure Monitoring Compared to Traditional Invasive and Non-invasive Blood Pressure Monitoring in Interventional Procedures: A Prospective, Single-Center, Self-Controlled Randomized Study","Inclusion Criteria:\n\n* Age ≥18 years\n* Patients scheduled for elective transradial interventional procedures requiring continuous invasive blood pressure monitoring\n* Patients who must undergo radial arterial catheterization for invasive blood pressure monitoring according to clinical needs and standard medical operational procedures\n* Patients who can understand the study purpose, voluntarily participate and sign informed consent, and are willing to undergo relevant examinations and clinical follow-up\n\nExclusion Criteria:\n\n* Contraindications to radial artery access\n* Hemodynamic instability\n* Patients requiring postoperative continuous invasive blood pressure monitoring\n* Failure to obtain informed consent\n* Known severe aortic or subclavian artery stenosis or occlusion\n* Severe coagulation dysfunction (INR ≥2.0, platelet count \\\u003C75×10⁹\u002FL)\n* BMI \\>40 kg\u002Fm²\n* Severe heart failure (NYHA Class IV) or patients requiring emergency rescue with hemodynamic instability",{"count":151,"type":21},50,"This observational study aims to evaluate the accuracy and safety of pressure sensing sheath blood pressure monitoring compared to traditional invasive and non-invasive blood pressure monitoring methods during neuroendovascular interventional procedures.\n\nThe study will enroll 50 adult patients undergoing elective neuroendovascular procedures requiring general anesthesia and continuous invasive blood pressure monitoring. Blood pressure will be simultaneously measured using three methods: (1) pressure sensing sheath, (2) radial arterial line, and (3) non-invasive cuff monitoring.\n\nThe primary outcome is the accuracy of blood pressure measurements from the pressure sensing sheath compared to radial arterial line measurements. Secondary outcomes include the incidence of access site complications, procedure duration, patient comfort scores, and cost-effectiveness analysis.\n\nThis prospective, single-center study will be conducted at Shanghai Fourth People's Hospital Affiliated to Tongji University from August 2025 to May 2027.",[30,154],"Neuroendovascular Procedures",[156,157,158,159],"Pressure sensing sheath","Blood pressure monitoring","Invasive blood pressure","Neuroendovascular intervention","2026-07-13",{"date":134,"type":47},{"date":163,"type":47},"2025-08-01",{"date":165,"type":21},"2027-05-31",{"name":167,"class":109},"Shanghai Fourth People's Hospital Tongji University",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":176,"minAge":18,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":22,"phases":179,"briefSummary":180,"conditions":181,"keywords":183,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":79},"100628156","community-health-worker-coaching-to-reduce-cardiovascular-risk-among-women-after-a-hypertensive-disorder-of-pregnancy-100628156","NCT07457970","Community Health Worker Coaching to Reduce Cardiovascular Risk Among Women After a Hypertensive Disorder of Pregnancy","Community Health Worker Coaching to Reduce CVD Disease Risk Among Women After a Hypertensive Disorder of Pregnancy","HERHEART","Inclusion Criteria:\n\n* 28 weeks gestation\n* A current hypertensive disorders in pregnancy or chronic hypertension\n* Singletons\n* Access to phone\n* Plan to deliver at Prisma Health-Midlands Hospital.\n\nExclusion Criteria:\n\n* Multiples\n* Fetal anomaly\n* Don't speak English\n* Already delivered a baby greater than 14 days ago.","FEMALE",{"count":178,"type":21},240,[24],"The goal of this clinical trial is to find out whether an enhanced program works better than remote blood pressure monitoring (RBPM) alone for women who had high blood pressure during pregnancy. The enhanced program combines RBPM with a lifestyle program led by a community health worker (CHW).\n\nThe study will examine whether the enhanced program helps women better control their blood pressure, lowers their average resting blood pressure, improves heart health risk factors (such as weight, diet, physical activity), supports mental well-being, and reduces emergency department visits and hospital readmissions by 6 months after delivery.",[30,29,182],"Pregnancy",[184,185,157,186,187],"community health worker","lifestyle intervention","postpartum","Cardiovascular risk","2026-04-27",{"date":190,"type":47},"2026-05-04",{"date":192,"type":47},"2026-04-24",{"date":194,"type":21},"2029-07-15",{"name":196,"class":109},"University of South Carolina",{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":203,"eligibilityCriteria":204,"healthyVolunteers":62,"sex":17,"minAge":18,"maxAge":205,"enrollmentInfo":206,"targetDuration":4,"studyType":22,"phases":207,"briefSummary":208,"conditions":209,"keywords":214,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":79},"100630073","transcutaneous-auricular-vagus-nerve-stimulation-and-spirometry-sham-controlled-randomized-trial-100630073","NCT07482930","Transcutaneous Auricular Vagus Nerve Stimulation and Spirometry: Sham-Controlled Randomized Trial","Acute Effects Transcutaneous Auricular Vagus Nerve Stimulation on Spirometric Parameters in Healthy Individuals: A Sham-Controlled Randomized Study","taVNS-SPIRO","Inclusion Criteria:\n\n* Aged 18-40 years.\n* Healthy volunteers.\n* Able to perform spirometry and follow study instructions.\n* Provided written informed consent.\n\nExclusion Criteria:\n\n* Any cardiovascular disease, cardiac arrhythmia, hypertension, or related condition.\n* Any neurological disorder (e.g., diabetes mellitus, peripheral neuropathy, epilepsy).\n* Any diagnosed psychiatric disorder.\n* Any respiratory disease (e.g., asthma, chronic obstructive pulmonary disease).\n* Pregnancy or suspected pregnancy.\n* Ear conditions that prevent stimulation (infection, open wound, pain\u002Ftenderness) or presence of a piercing at\u002Fnear the stimulation site.\n* Vigorous exercise within 24 hours prior to measurement.\n* Caffeine intake, smoking, or alcohol consumption within 4-6 hours prior to measurement.\n* Marked intolerance or hypersensitivity to the device or the procedure.\n* Inability to follow instructions during measurements or refusal to complete the session.","40 Years",{"count":151,"type":21},[24],"This study will examine the short-term effects of transcutaneous auricular vagus nerve stimulation (a non-invasive electrical stimulation delivered through the outer ear) on lung function measured by spirometry in healthy adults. The vagus nerve is involved in many automatic body functions, and ear-based stimulation has been used in research to explore its possible effects on different physiological systems. However, it is not clear whether a brief stimulation session can acutely influence breathing test results in people without respiratory disease.\n\nHealthy volunteers aged 18-40 will take part in one laboratory visit. Participants will be randomly assigned to one of two groups: (1) active bilateral stimulation applied to specific ear regions that are known to be innervated by the vagus nerve, or (2) sham stimulation using the same device setup but designed to minimize vagal activation. The stimulation session will last approximately 10 minutes. Before and after the stimulation, participants will perform standard spirometry (breathing) tests. Primary spirometric outcomes will include common measures of lung function such as forced vital capacity (FVC), forced expiratory volume in one second (FEV1), and peak expiratory flow (PEF). Heart rate, heart rate variability, and blood pressure may also be recorded to monitor physiological responses and safety during the visit.\n\nParticipation is voluntary and participants may withdraw at any time. The procedure is considered minimal risk. Possible side effects are usually mild and temporary, such as tingling, warmth, or mild discomfort at the ear. Rarely, participants may feel lightheaded; if this occurs, the procedure will be stopped and the participant will be monitored until symptoms resolve. There is no guaranteed direct benefit to participants. The results may help clarify whether short-term ear-based vagus nerve stimulation can influence spirometric parameters and may inform future studies on autonomic and respiratory interactions.",[210,211,212,30,213],"Vagus Nerve Stimulations","Spirometry","Autonomic Nervous System (ANS) Functioning and Mood State","Respiratory Function Tests",[215,216,217,218,219,220],"transcutaneous auricular vagus nerve stimulation","spirometry","autonomic nervous system","sham stimulation","pulmonary function test","blood pressure","2026-03-16",{"date":223,"type":47},"2026-03-19",{"date":225,"type":47},"2026-03-17",{"date":227,"type":21},"2026-04-25",{"name":229,"class":109},"SEFA HAKTAN HATIK",{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":236,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":238,"enrollmentInfo":239,"targetDuration":4,"studyType":22,"phases":241,"briefSummary":243,"conditions":244,"keywords":247,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":79},"100615618","phase-3-impact-of-semaglutide-withdrawal-on-cardiometabolic-profile-and-physiology-of-energy-balance-recovery-effects-after-semaglutide-termination-100615618","NCT07294950","Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination","Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: a Randomized Controlled Trial Comparing Gradual Dose Reduction With Immediate Treatment Cessation.","REST","Inclusion Criteria:\n\n* Men and women with previously diagnosed BMI ≥ 30 kg\u002Fm2 or BMI ≥ 27 kg\u002Fm2 and adiposity-related complications (such as osteoarthritis, nonalcoholic liver disease, sleep apnea, and hypertension) without preexisting cardiovascular disease or type 2 diabetes.\n* Age 18 - 75 years inclusive\n* Ongoing weight-loss treatment consisting of weekly subcutaneous semaglutide at minimum dose of 1 mg\u002Fweekly with documented weight reduction of at least 10% of pre-treatment body weight\n* Stable weight over past 12 weeks (less than 5% change in body weight) (self-reported)\n* Ability to read and understand English\n\nExclusion Criteria:\n\n* Previously diagnosed cardiovascular disease defined as previous myocardial infarction, previous stroke, or symptomatic peripheral arterial disease.\n* Currently pregnant or lactating\n* Previously diagnosed type 2 diabetes\n* Use of any other pharmacological treatment for weight-loss\n* Previous surgical treatment for weight loss such as gastric bypass or gastric band\n* Any history of eating disorder\n* Renal dysfunction as evidenced by estimated glomerular filtration rate \\\u003C 25 ml\u002Fmin by CKD-EPI Creatinine Equation\n* New York Heart Association class II-IV heart failure\n* Hepatic disease considered to be clinically significant (includes jaundice, chronic hepatitis, or previous liver transplant) or transaminases \\>2.5X the upper limit of normal\n* Malignant neoplasm requiring chemotherapy, surgery, radiation or palliative therapy within the previous 5 years (with the exception of basal cell skin cancer)\n* Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2\n* Any other factor likely to limit adherence to the study, in the opinion of the investigators","75 Years",{"count":240,"type":21},98,[242],"PHASE3","Semaglutide is a medication from the class of drugs called glucagon-like peptide-1 agonists that promote weight loss. There is little clinical data on the best strategy to achieve weight maintenance following weight reduction induced by semaglutide. For people who need to discontinue treatment, it is unknown whether the weight regain, its accompanied health benefits could be ameliorated with a gradual reduction in semaglutide. The investigators will study if a gradual reduction of semaglutide is associated with different heart risk profile and hormones involved in energy regulation as compared to immediate treatment cessation.",[245,125,30,246],"Obesity (Disorder)","Appetite Regulation",[248,249],"Randomized controlled trial","Interventional","2026-02-09",{"date":252,"type":47},"2026-02-11",{"date":254,"type":47},"2026-02-01",{"date":256,"type":21},"2029-05",{"name":258,"class":109},"Mount Sinai Hospital, Canada",{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":62,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":266,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":268,"conditions":269,"keywords":270,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":79},"100615797","evaluating-the-level-of-agreement-between-aamieshiso-universal-standard-requirements-and-the-huawei-d2-watch-type-wrist-blood-pressure-monitor-100615797","NCT07297277","Evaluating the Level of Agreement Between AAMI\u002FESH\u002FISO Universal Standard Requirements and the HUAWEI D2 Watch-Type Wrist Blood Pressure Monitor","An Observational Cross-Sectional Blind Comparison to Evaluate the Level of Agreement Between AAMI\u002FESH\u002FISO Universal Standard Requirements and the HUAWEI D2 Watch-Type Wrist Blood Pressure Monitor","Inclusion Criteria:\n\n* Age \\>18 years\n* Written informed consent provided\n\nExclusion Criteria:\n\n* Cardiac Arrythmias\n* Peripheral Arterial Disease\n* Known Heart Disease\n* Pregnancy\n* Diagnosis of Secondary Hypertension",{"count":267,"type":21},85,"Getting an accurate blood pressure (BP) reading is essential for diagnosing high blood pressure and managing it effectively. High blood pressure is a major health problem, causing about 9.4 million deaths worldwide each year. More people need to monitor their BP at home, so there is greater demand for easy-to-use devices. Traditional BP monitors with arm cuffs can be bulky, uncomfortable, and awkward to use.\n\nModern technology has made it possible to measure BP using wearable devices like smartwatches. HUAWEI has developed a wrist watch that can measure BP and has been tested to meet international standards. The watch passed these tests and was approved for people to use at home to check their own BP. However, the HUAWEI watch was only tested on people in China and the investigators need to know if it works for people from other countries and ethnic backgrounds.",[30],[27,271,272,273,274],"Auscultatory","Oscillometric","Watch Type Monitor","Validation","2025-12-22",{"date":277,"type":47},"2025-12-30",{"date":279,"type":47},"2025-07-15",{"date":281,"type":21},"2027-10",{"name":283,"class":109},"Northumbria University",{"id":285,"slug":286,"hasResults":11,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":4,"eligibilityCriteria":290,"healthyVolunteers":62,"sex":176,"minAge":18,"maxAge":291,"enrollmentInfo":292,"targetDuration":4,"studyType":22,"phases":294,"briefSummary":295,"conditions":296,"keywords":301,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":79},"100597918","effect-of-music-and-warm-foot-bath-therapy-on-pregnancy-related-anxiety-blood-pressure-and-quality-of-life-100597918","NCT07064733","Effect of Music and Warm Foot Bath Therapy on Pregnancy-Related Anxiety, Blood Pressure and Quality of Life","A Randomized Controlled Trial on the Effect of Music Therapy and Warm Foot Bath Therapy on Anxiety, Blood Pressure, and Quality of Life in Low-Risk Primigravida Pregnant Women","Inclusion Criteria:\n\n* 18-39 years of age,\n\n  * Literate; able to make an informed decision to participate, communicate verbally, and sign a consent form\n  * Pregnant with a single, live fetus\n  * Have a smartphone\n  * Low-risk primigravida pregnant with a gestational age of 26 weeks or more\n\nExclusion Criteria:\n\n* \\- Having hearing impairment,\n* Refusing to participate,\n* Being illiterate,\n* Having communication problems,\n* Being hospitalized with severe preeclampsia,\n* The newborn not surviving.\n* Antepartum hemorrhage\n* Preeclampsia,\n* Gestational hypertension,\n* Cervical insufficiency,\n* Having pregnancy-related complications such as congenital fetal anomalies and intrauterine growth restriction diagnosed before 28 weeks of gestation or having multiple pregnancies;\n* Having psychiatric disorders (known anxiety or depression, other illnesses),\n* Having medical problems such as endocrine disorders (gestational diabetes mellitus, thyroid dysfunction, etc.);\n* Having assisted reproductive techniques (ART) such as in vitro fertilization, embryo transfer, or\n* Pregnant women at risk of preterm birth will not be included in the study.","39 Years",{"count":293,"type":21},144,[24],"Study Title:\n\nThe Effects of Music Therapy and Warm Foot Bath on Pregnancy-Related Stress, Blood Pressure, and Quality of Life in Low-Risk Primigravida Women\n\nBrief Summary:\n\nThis randomized controlled trial investigates the impact of music therapy and warm foot bath therapy on pregnancy-related anxiety, blood pressure levels, and quality of life in low-risk primigravida pregnant women. Participants will be randomly assigned into four groups: music therapy, warm foot bath therapy, combined therapy, and control group. The interventions will be carried out for 2 weeks with pre- and post-assessments of anxiety and quality of life.",[297,298,30,299,300],"Primigravida Women","Music Therapy","Quality of Life","Anxiety",[302,303,304,299,220],"primigravida","music therapy","Warm Foot Bath","2025-07-11",{"date":279,"type":47},{"date":308,"type":47},"2025-06-06",{"date":310,"type":21},"2026-04-01",{"name":312,"class":109},"Kırklareli University",{"id":314,"slug":315,"hasResults":11,"nctId":316,"briefTitle":317,"officialTitle":317,"acronym":4,"eligibilityCriteria":318,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":319,"targetDuration":4,"studyType":22,"phases":320,"briefSummary":321,"conditions":322,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":79},"100596949","non-invasive-blood-pressure-monitoring-in-icu-patients-using-the-dare-device-100596949","NCT07052123","Non-Invasive Blood Pressure Monitoring in ICU Patients Using the DARE Device","Inclusion Criteria:\n\n* Adult patients (male or female), aged 18 years or older\n* Admitted to intensive care unit (ICU) or critical care with an expected hospital stay longer than 2 days\n* Equipped with an arterial catheter for invasive blood pressure monitoring\n* Equipped with a urinary catheter for invasive core body temperature monitoring\n\nExclusion Criteria:\n\n* Patients under 18 years old (minors)\n* Known skin allergy to adhesives or silicone, or skin condition preventing adhesive use\n* History of extensive skin pathology (e.g., Lyell syndrome)\n* Patients with therapeutic limitations\n* Patients with active implanted medical devices (e.g., pacemaker, defibrillator)\n* Pregnant or breastfeeding women\n* Patients not affiliated with the French social security system\n* Patients or their legal representatives refusing consent, or unable to understand information and give informed consent\n* Patients under legal guardianship, curatorship, or deprived of liberty",{"count":110,"type":21},[24],"This study tests a new non-invasive device called DARE to monitor blood pressure in patients in intensive care. It compares the device's readings to standard invasive methods and also looks at how well it measures other vital signs like temperature, oxygen levels, and heart rhythm. The goal is to improve patient safety and comfort while helping doctors detect problems earlier.",[323,30,324,325,326],"Hemodynamics","Intensive Care Units","Critical Illness","Monitoring, Physiologic","2025-06-26",{"date":329,"type":47},"2025-07-04",{"date":331,"type":47},"2025-03-24",{"date":333,"type":21},"2028-03-24",{"name":335,"class":109},"Centre Hospitalier de Saint-Denis"]